In that sense, the blockade of this PD-1/PD-L1 interaction by specific mAbs (a-PD-1 or a-PD-L1) has demonstrated tumor eradication and has contributed to the enhancement of other cancer therapies [9,10]. This evidence concerns the gene CD274 and neoplasm.